Hematological Oncology最新文献

{"title":"Discovery Science highlights from the 17th International Conference on Malignant Lymphoma","authors":"Gabriela Forestieri,&nbsp;Joyce Marques de Almeida,&nbsp;Sara Napoli,&nbsp;Deborah Piffaretti,&nbsp;Chiara Tarantelli,&nbsp;Fangwen Zhang,&nbsp;Afua Adjeiwaa Mensah","doi":"10.1002/hon.3275","DOIUrl":"https://doi.org/10.1002/hon.3275","url":null,"abstract":"<p>Since its inception over 4 decades ago, the International Conference on Malignant Lymphoma (ICML) has steadily grown to become the leading international forum for lymphoma experts. Now with a biennial occurrence and more than 3000 participants, the ICML provides a unique opportunity for lymphoma clinicians, healthcare workers and scientists to come together and discuss novel data gleaned from discovery science, translational research, and clinical research efforts. Many pivotal findings in the lymphoma research community were first reported at ICML meetings and some of these have driven practice-changing approaches in lymphoma patient care.</p><p>As lymphoma scientists working at the Institute of Oncology Research in Bellinzona, Switzerland, we are proud to be involved in the ICML. In collaboration with Women in Lymphoma, we are excited to present to you our selected <i>Discovery Science highlights</i> from the 17th ICML meeting. Our aim is for these highlights to complement the clinical take-home messages presented at the <i>17-ICML highlights</i> session and as such champion the importance of collaborative research which combines the expertise of clinical and non-clinical investigators, for the effective prevention, diagnosis and treatment of lymphomas.</p><p>Over the years, the work of a multitude of lymphoma researchers together with the emergence of new technologies, have resulted in a richer understanding of the molecular features that initiate and support lymphomagenesis. Laura Pasqualucci (New York, USA), is aptly recognised as having made seminal contributions to our understanding of lymphoma biology and as such, a number of her team's findings featured in her <i>Meet the Professor</i> session,<span>¹</span> which focused on the role of the germinal center (GC) in the genesis of lymphomas. After giving an authoritative overview of the genetic, epigenetic and microenvironmental perturbations involved in the pathogenesis of lymphomas originating from the GC, she explained how she and Riccardo Dalla-Favera (New York, USA), embarked on opening the “big black box” that is the non-coding human genome to better study GC-derived lymphomas. Their investigations revealed that superenhancers (SE) were frequently hypermutated in diffuse large B cell lymphomas (DLBCLs). Over 90% of DLBCLs were found to harbor at least two mutations within SE regions thus indicating a selective pressure to acquire mutations in these regulatory domains. The activation induced cytidine deaminase, AID, was identified as a central player in the introduction of these mutations and the SE of key genes involved in lymphomagenesis were among those targeted. Working in the lab of Riccardo Dalla-Favera and Laura Pasqualucci, Elodie Bal, whose investigations uncovered this frequent targeting of SE in DLBCL, described her findings in more detail in two different sessions, <i>Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas</i> and <i>Lymphoma ","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation","authors":"José Carlos Jaime-Pérez,&nbsp;Marcela Hernández-Coronado,&nbsp;Mariana González-Treviño,&nbsp;Renata V. Barragán-Longoria,&nbsp;Eugenia M. Ramos-Dávila,&nbsp;David Gómez-Almaguer","doi":"10.1002/hon.3271","DOIUrl":"https://doi.org/10.1002/hon.3271","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140546857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203","authors":"Takashi Watanabe,&nbsp;Yoshihiro Matsuno,&nbsp;Masashi Wakabayashi,&nbsp;Dai Maruyama,&nbsp;Kazuhito Yamamoto,&nbsp;Nobuko Kubota,&nbsp;Kazuyuki Shimada,&nbsp;Kohsuke Asagoe,&nbsp;Motoko Yamaguchi,&nbsp;Kiyoshi Ando,&nbsp;Michinori Ogura,&nbsp;Junya Kuroda,&nbsp;Youko Suehiro,&nbsp;Kunihiro Tsukasaki,&nbsp;Kensei Tobinai,&nbsp;Hirokazu Nagai","doi":"10.1002/hon.3272","DOIUrl":"https://doi.org/10.1002/hon.3272","url":null,"abstract":"<p>Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment, we performed this post-hoc analysis of patients with advanced indolent B-cell lymphoma in a randomized clinical trial wherein six cycles of R-CHOP were administered every 2–3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676–9.466) and high- (OR 2.236, 95% CI 0.160–31.226) risks, B symptoms (OR 2.091, 95% CI 0.747–5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634–5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow-up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806–8.575) and high-risk FLIPI (OR 4.401, 95% CI 0.186–104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analysis had a greater impact on HT. G3A and high-risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced-stage FL in future trials, particularly to address the unmet needs of patients with POD24.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140541039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis","authors":"Maria Livia Del Giudice,&nbsp;Sara Galimberti,&nbsp;Gabriele Buda","doi":"10.1002/hon.3270","DOIUrl":"https://doi.org/10.1002/hon.3270","url":null,"abstract":"<p>Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti-amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group","authors":"Xinyu Li,&nbsp;Shaofen Lin,&nbsp;Ning Liao,&nbsp;Huirong Mai,&nbsp;Xingjiang Long,&nbsp;Lili Liu,&nbsp;Beiyan Wu,&nbsp;Qiwen Chen,&nbsp;Qian Kong,&nbsp;Xianling Kong,&nbsp;Lixia Liu,&nbsp;Jiayue Qin,&nbsp;Jianpei Fang,&nbsp;Dunhua Zhou","doi":"10.1002/hon.3265","DOIUrl":"https://doi.org/10.1002/hon.3265","url":null,"abstract":"<p>The next-generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the <i>RAS</i> signaling pathway mutation spectrum and the related prognosis in pediatric ALL. We employed an NGS panel comprising 220 genes. NGS results were collected from 202 pediatric ALL patients. 155 patients (76.7%) harbored at least one mutation. The incidences of <i>RAS</i> signaling pathway mutations are different significantly between T-ALL and B-ALL. In B-ALL, the <i>RAS</i> pathway is mostly involved, and <i>NRAS</i> (17.6%), <i>KRAS</i> (22.7%), and <i>PTPN11</i> (7.7%) were the three most frequently mutated genes. Co-occurring mutations of <i>CREBBP</i> and <i>NRAS</i>, <i>FLT3</i>, or <i>PTPN11</i> (<i>p</i> = 0.002, <i>p</i> = 0.009, and <i>p</i> = 0.003, respectively) were found in this cohort. The 3-year RFS rates for the <i>RAS</i> signaling pathway mutation-positive and negative cases was 76.5 % versus 89.7 % (<i>p</i> = 0.012). Four cases relapsed in the lately 3 years were <i>RAS</i> signaling pathway mutation-positive. <i>RAS</i> signaling pathway mutation is an important biomarker for poorer relapse-free survival in pediatric B-ALL patients despite good early MRD levels.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140343061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia","authors":"Yuan Sun,&nbsp;Xu Wang,&nbsp;Wen-Min Chen,&nbsp;Yue Hao,&nbsp;Ling-Di Li,&nbsp;Jin-Ying Li,&nbsp;Kai Sun,&nbsp;Zong-Yan Shi,&nbsp;Hao Jiang,&nbsp;Qian Jiang,&nbsp;Xiao-Jun Huang,&nbsp;Ya-Zhen Qin","doi":"10.1002/hon.3264","DOIUrl":"10.1002/hon.3264","url":null,"abstract":"<p>In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT^mut) DNA level is reportedly predictive of relapse in <i>t</i> (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT^mut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 <i>t</i> (8; 21) AML patients with KIT^mut (D816V/H/Y or N822K) were tested for KIT^mut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT^mut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT^mut-high (KIT_H) group and the KIT^mut-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (<i>p</i> = 0.0040 and 0.021, respectively) and Course 2 consolidation (<i>p</i> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with &gt;3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KIT^mut and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in <i>t</i> (8; 21) AML patient with KIT mutation.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement","authors":"Elisabetta M. Abenavoli,&nbsp;Flavia Linguanti,&nbsp;Matilde Anichini,&nbsp;Vittorio Miele,&nbsp;Francesco Mungai,&nbsp;Marianna Palazzo,&nbsp;Luca Nassi,&nbsp;Benedetta Puccini,&nbsp;Ilaria Romano,&nbsp;Benedetta Sordi,&nbsp;Roberto Sciagrà,&nbsp;Gabriele Simontacchi,&nbsp;Alessandro M. Vannucchi,&nbsp;Valentina Berti","doi":"10.1002/hon.3261","DOIUrl":"10.1002/hon.3261","url":null,"abstract":"<p>To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F-FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast-Enhanced Computed Tomography scan (CECT), together with clinical data, in predicting first-line therapy refractoriness (R) of classical HL (cHL) with mediastinal bulk involvement. We reviewed 69 cHL patients who underwent staging PET and CECT. Lesion segmentation and texture parameter extraction were performed using the freeware software LIFEx 6.3. The prognostic significance of clinical and imaging features was evaluated in relation to the development of refractory disease. Receiver operating characteristic curve, Cox proportional hazard regression and Kaplan-Meier analyses were performed to examine the potential independent predictors and to evaluate their prognostic value. Among clinical characteristics, only stage according to the German Hodgkin Group (GHSG) classification system significantly differed between R and not-R. Among CECT variables, only parameters derived from second order matrices (gray-level co-occurrence matrix (GLCM) and gray-level run length matrix (GLRLM) demonstrated significant prognostic power. Among PET variables, SUVmean, several variables derived from first (histograms, shape), and second order analyses (GLCM, GLRLM, NGLDM) exhibited significant predictive power. Such variables obtained accuracies greater than 70% at receiver operating characteristic analysis and their PFS curves resulted statistically significant in predicting refractoriness. At multivariate analysis, only HISTO_EntropyPET extracted from PET (HISTO_Entropy_PET) and GHSG stage resulted as significant independent predictors. Their combination identified 4 patient groups with significantly different PFS curves, with worst prognosis in patients with higher HISTO_Entropy_PET values, regardless of the stage. Imaging radiomics may provide a reference for prognostic evaluation of patients with mediastinal bulky cHL. The best prognostic value in the prediction of R versus not-R disease was reached by combining HISTO_Entropy_PET with GHSG stage.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model","authors":"Maria Anele Romeo,&nbsp;Chiara Focaccetti,&nbsp;Andrea Arena,&nbsp;Rossella Benedetti,&nbsp;Michele Di Crosta,&nbsp;Camilla Palumbo,&nbsp;Maria Saveria Gilardini Montani,&nbsp;Roberta Santarelli,&nbsp;Roberta Gonnella,&nbsp;Gabriella D’Orazi,&nbsp;Roberto Bei,&nbsp;Mara Cirone","doi":"10.1002/hon.3262","DOIUrl":"10.1002/hon.3262","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140049205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of baseline 2-[18F]-FDG-PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis","authors":"Domenico Albano,&nbsp;Anna Calabrò,&nbsp;Francesco Dondi,&nbsp;Samuele Bagnasco,&nbsp;Alessandra Tucci,&nbsp;Francesco Bertagna","doi":"10.1002/hon.3266","DOIUrl":"10.1002/hon.3266","url":null,"abstract":"<p>Diffuse Large B-Cell Lymphomas (DLCBL) and mucosa-associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[¹⁸F]-FDG-PET/CT) and radiomics features (RFs) in predicting the final diagnosis of patients with PGLs. Ninety-one patients with newly diagnosed PGLs who underwent pre-treatment 2-[¹⁸F]-FDG-PET/CT were included. PET images were qualitatively and semi-quantitatively analyzed by deriving maximum standardized uptake value body weight (SUVbw), maximum standardized uptake value lean body mass (SUVlbm), maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume (gMTV) and total lesion glycolysis of gastric lesion (gTLG), total MTV (tMTV), TLG, and first-order RFs (histogram-related and shape related). Receiver-operating characteristic (ROC) curve analyses were performed to determine the differential diagnostic values of PET parameters. The final diagnosis was DLBCL in 54 (59%) cases and MALT in 37 cases (41%). PGLs showed FDG avidity in 83 cases (90%), 54/54 of DLBCL and 29/37 of MALT. All PET/CT metabolic features, such as stage of disease and tumor size, were significantly higher in DLBCL than MALT; while the presence of <i>H. Pylori</i> infection was more common in MALT. At univariate analysis, all PET/CT metrics were significantly higher in DLBCL than MALT lymphomas, while among RFs only Shape volume_vx and Shape sphericity showed a significant difference between the two groups. In conclusion we demonstrated that 2-[¹⁸F]-FDG-PET/CT parameters can potentially discriminate between DLBCL and MALT lymphomas with high accuracy. Among first-order RFs, only Shape volume_vx and Shape sphericity helped in the differential diagnosis.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy","authors":"Enrico Grande,&nbsp;Francesco Grippo,&nbsp;Claudio Barbiellini Amidei,&nbsp;Ugo Fedeli,&nbsp;Alberto Tosetto","doi":"10.1002/hon.3263","DOIUrl":"10.1002/hon.3263","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}